Antipsychotic Polypharmacy: Helpful or Harmful?

Prescribing two antipsychotics to a single patient is a common practice in clinical settings. Increasingly, we are bing scolded for this practice. If possible, stick with a single antipsychotic. But if the situation seems to call for polypharmacy, here are some factors to guide your decision-making.

Latuda: An Evaluation of Its Usefulness

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

Glutamate’s Role in Schizophrenia

Schizophrenia - The Carlat Psychiatry Report (TCPR)

There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so.

Research Update

The New Three-Month Version of Injectable Paliperidone: Should You Use It?

Patients with schizophrenia often stop taking their medications, so long-acting injectable antipsychotics (LAIs) are potentially good ways to make sure these patients have some medication in their systems over the long term.

Some Popular Antipsychotics May Not be Effective in Patients over 40

Atypical antipsychotics are widely prescribed for a number of psychiatric diagnoses, but their real-world effectiveness has rarely been evaluated in anything other than short-term trials. A recently published study finds that four commonly used antipsychotics (aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], and risperidone [Risperdal]), when used in patients over age 40 with schizophrenia or psychosis associated with other conditions, may not be effective—and cause frequent side effects.

Expert QA

Attenuated Psychosis Syndrome

Dr. Carpenter, you are a member of the DSM-5 work group that is considering risk syndrome for first psychosis, or what is now called “attenuated psychosis syndrome” as a new diagnosis in the manual.

Free Article

Foster Care and Child Psychiatry: A Primer [Free Article]

Nearly one in three foster children have significant psychiatric problems during their time in foster care—especially those related to trauma and neglect that brought them into the system. This article is a brief primer on how foster care works, and how psychiatrists get involved.

The Psychosis Prodrome [Free Article]

The Carlat Psychiatry Report - TCPR - January 2013

At the crossroads of these experiences lies the concept of the psychosis prodrome and early intervention/prevention efforts. But without evidence of a florid psychotic episode, when should one intervene?

Latuda: “Procognitive” or Pro-Profit? [Free Article]


Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?